Related references
Note: Only part of the references are listed.Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Felipe Batalini et al.
CLINICAL CANCER RESEARCH (2022)
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D. Choudhury et al.
CLINICAL CANCER RESEARCH (2022)
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Simon Eschweiler et al.
NATURE (2022)
Ropivacaine inhibits wound healing by suppressing the proliferation and migration of keratinocytes via the PI3K/AKT/mTOR Pathway
Xiaoyang Wu et al.
BMC ANESTHESIOLOGY (2022)
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
Lindsey E. Roeker et al.
CLINICAL CANCER RESEARCH (2022)
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
Matthew S. Davids et al.
LEUKEMIA (2021)
Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial
H-Y Yhim et al.
ANNALS OF ONCOLOGY (2021)
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
Franck Morschhauser et al.
LEUKEMIA (2021)
Dominant Role of PI3K p110α over p110β in Insulin and β-Adrenergic Receptor Signalling
Biqin Zhang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H. Fowler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
Javier Munoz et al.
TARGETED ONCOLOGY (2021)
Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity
Kelvin Anderson et al.
CANCERS (2021)
Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype
Ralitsa Madsen et al.
PLOS GENETICS (2021)
Synergistic efficacy of the dual PI3K-d/g inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models
Andrea Iannello et al.
BLOOD (2021)
Umbralisib: First Approval
Sohita Dhillon et al.
DRUGS (2021)
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Rosalin Mishra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J. Matasar et al.
LANCET ONCOLOGY (2021)
Copanlisib safe and active in combination
David Killock
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
The PI3K partial differential -Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
Lisa Rohrbacher et al.
FRONTIERS IN IMMUNOLOGY (2021)
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenstrom macroglobulinemia
Cecile Tomowiak et al.
BLOOD ADVANCES (2021)
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
Christiane Braun et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3K beta Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2021)
Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)
Dandan Meng et al.
PHARMACOLOGICAL RESEARCH (2021)
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
Ninghui Mao et al.
NATURE COMMUNICATIONS (2021)
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S. Davids et al.
BLOOD ADVANCES (2021)
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
Miriam Marques et al.
CANCER RESEARCH (2020)
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Georg Lenz et al.
LEUKEMIA (2020)
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2020)
Inhibition of Phosphatidylinositol 3-Kinase γ by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice
Rui Liu et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2020)
Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment
Min Jiang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
p110 δ PI3K as a therapeutic target of solid tumours
Lydia Xenou et al.
CLINICAL SCIENCE (2020)
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
Victor McPherson et al.
CANCER (2020)
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
Mark Rosenthal et al.
ESMO OPEN (2020)
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
Kamira Maharaj et al.
BLOOD ADVANCES (2020)
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Antonio Cuneo et al.
HEMATOLOGICAL ONCOLOGY (2019)
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PIK3CA in cancer: The past 30 years
Rand Arafeh et al.
SEMINARS IN CANCER BIOLOGY (2019)
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Ariella B. Hanker et al.
CANCER DISCOVERY (2019)
Critical roles for the phosphatidylinositide 3-kinase isoforms p110β and p110γ in thrombopoietin-mediated priming of platelet function
Samantha F. Moore et al.
SCIENTIFIC REPORTS (2019)
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J. Nastoupil et al.
LANCET HAEMATOLOGY (2019)
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review
Angela Esposito et al.
JAMA ONCOLOGY (2019)
Targeting PI3K signaling in cancer: Challenges and advances
Maria Chiara De Santis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
Angela Molinaro et al.
CELL METABOLISM (2019)
P110β in the ventromedial hypothalamus regulates glucose and energy metabolism
Teppei Fujikawa et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2
Lei Zhou et al.
NATURE (2019)
PI3K isoforms in cell signalling and vesicle trafficking
Benoit Bilanges et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity
Carolina Torres et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Enhanced β-adrenergic signalling underlies an age-dependent beneficial metabolic effect of PI3K p110α inactivation in adipose tissue
Caroline Araiz et al.
NATURE COMMUNICATIONS (2019)
The use of buparlisib as a radiosentisiser: What about toxicity?
Peter A. van Dam
EUROPEAN JOURNAL OF CANCER (2019)
Inhibiting PI3 kinase-γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors
Xueqiong Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway
Jing-Yuan Li et al.
STEM CELL RESEARCH & THERAPY (2019)
Function, Regulation and Biological Roles of PI3Kγ Variants
Bernd Nuernberg et al.
BIOMOLECULES (2019)
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Management of toxicity to isoform α-specific PI3K inhibitors
S. E. Nunnery et al.
ANNALS OF ONCOLOGY (2019)
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
Bruce D. Cheson et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
Giuseppe Curigliano et al.
DRUG SAFETY (2019)
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial
Dejan Juric et al.
JAMA ONCOLOGY (2019)
Structural Determinants of Isoform Selectivity in PI3K Inhibitors
Michelle S. Miller et al.
BIOMOLECULES (2019)
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia
Benjamin L. Lampson et al.
BLOOD ADVANCES (2019)
A slowly developed severe cutaneous adverse reaction to idelalisib
L. Huilaja et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
PIK3CB/p110 beta is a selective survival factor for glioblastoma
Kevin J. Pridham et al.
NEURO-ONCOLOGY (2018)
PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis
Pallavi Varshney et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth
Mingchuan Li et al.
CIRCULATION (2018)
Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition
A. K. Dewan et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2018)
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and
Evangelia Goulielmaki et al.
CELL DEATH & DISEASE (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
The Isoform Selective Roles of PI3Ks in Dendritic Cell Biology and Function
Ezra Aksoy et al.
FRONTIERS IN IMMUNOLOGY (2018)
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Steven M. Horwitz et al.
BLOOD (2018)
PI3K-selective and PI3K/-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
Benjamin L. Lampson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
Denis Soulieres et al.
LANCET ONCOLOGY (2017)
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Xiaohong Zhao et al.
NATURE COMMUNICATIONS (2017)
CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells
Jing Zhang et al.
CELL REPORTS (2017)
Inhibiting PI3Kb with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
James T. Lynch et al.
CLINICAL CANCER RESEARCH (2017)
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Joaquin Mateo et al.
CLINICAL CANCER RESEARCH (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
Paul M. Barr et al.
BLOOD (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β
Yoshito Nakanishi et al.
CANCER RESEARCH (2016)
Idelalisib-related pneumonitis
Eglantine Haustraete et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition
Hua-Fu Zhao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management
Jonathan W. Goldman et al.
ONCOLOGIST (2016)
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
Jacqueline C. Barrientos
ONCOTARGETS AND THERAPY (2016)
The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
Kruti Sheth Nair et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
The Multifaceted Roles of PI3Kγ in Hypertension, Vascular Biology, and Inflammation
Marialuisa Perrotta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Idelalisib-associated Enterocolitis Clinicopathologic Features and Distinction From Other Enterocolitides
Christine Y. Louie et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Idelalisib-associated Colitis Histologic Findings in 14 Patients
Anna-Sophie Weidner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling
Marius Vantler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Qingshan Yang et al.
CLINICAL CANCER RESEARCH (2015)
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
Rute B. Marques et al.
EUROPEAN UROLOGY (2015)
Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethy12-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and P13Kδ for the Treatment of PTEN-Deficient Cancers
Bernard Barlaam et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs Hancox et al.
MOLECULAR CANCER THERAPEUTICS (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
L. Albiges et al.
ANNALS OF ONCOLOGY (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ
Jennifer K. Uno et al.
GASTROENTEROLOGY (2010)
Share Paper
